The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

The Role of PET in Staging Non-Small Cell Lung Cancer

비소세포 폐암의 병기 결정에서 F-18 FDG PET의 역할

  • Hyun, In-Young (Departments of Nuclear Medicine, Inha University College of Medicine)
  • 현인영 (인하대학교 의과대학 핵의학교실)
  • Published : 2004.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Lung cancer has become a leading cause of cancer death in Korea. Accurate staging of non-small cell lung cancer (NSCLC) is essential to the ability to offer a patient the most effective available treatment and the best estimate of prognosis. PET with F-18 fluorodeoxyglucose (FDG) is indicated for the nodal staging of NSCLC and detection of distant metastases. Use of PET for mediastinal staging should not be relied on as a sole staging modality, and positive findings should be confirmed by mediastinoscopy. FDG PET avoids futile surgery by a more accurate selection of patients, especially by the detection of unexpected distant metastases.

Keywords

References

  1. Annual report of the Korea central cancer registry: Based on registered data from 134 hospitals. Ministry of Health and Welfare. 2003
  2. Detterbeck FC, Falen S, Rivera MP, Halle JS, Socinski MA. Defining the appropriate phase for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest 2004;125:2300-8 https://doi.org/10.1378/chest.125.6.2300
  3. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(5 Suppl):1S-93S
  4. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s; meta-analytic comparison of PET and CT. Radiology 1999;213:530-6
  5. Baum RP, Hellwig D, Mezetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med Mol Imaging 2004;48:119-42
  6. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1575-81; discussion 1581-2
  7. Bury T, Dowlati A. Paulus P, Corhay JL, Hustinx R, Ghaye B, et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997;10:2529-34 https://doi.org/10.1183/09031936.97.10112529
  8. Vansteenkiste JF, Strobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations form 68 patients. J Clin Oncol 1998;16:2142-9
  9. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803-9 https://doi.org/10.1148/radiology.212.3.r99se21803
  10. Liewald F, Grosse S, Storck M, Guhlmann A, Halter G, Reske S, et al. How useful is positron emission tomography for lymph-node staging in non-small lung cancer? Thorac Cardiovasc Surg 2000;48:93-6
  11. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2003;343:254-61 https://doi.org/10.1056/NEJM200007273430404
  12. Roberts PF, Follette DM, con Haag D, Park JA, Valk PE, Pounds TR, et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg 2000;70:1154-9; discussion 1159-60
  13. Poncelet AJ, Lonneux M, Coche E, Weynand B, Noirhomme P. PET-FDG scan enhances but dose not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardiothorac Surg 2001;20: 468-74; discussion 474-5
  14. Kernstine KH, Mclaughlin KA, Menda Y, Rossi NP, Kahn DJ, Bushnell DL, et al. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable non-small cell lung cancer? Ann Thorac Surg 2002;73:394-401; discussion 402
  15. Vesselle H, Pugsley JM, Vallieres E, Wood DE. The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer. J Thorac cardiovasc Surg 2002;124:511-9 https://doi.org/10.1067/mtc.2002.123130
  16. Von Haag DW, follette DM, Roberts PF, Shelton D, Segel LD, Taylor TM. Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer. J Surg res 2002;103:160-4 https://doi.org/10.1006/jsre.2002.6354
  17. Detterbeck FC, Jones DR, Parker LA Jr. Intrathoracic staging. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and treatment of lung cancer: and evidence bases guide for the practicing clinician. Philadelphia, PA: W.D. Saunders, 2001;73-93
  18. Kim B-T. The role of PET in lung cancer Korean J Nucl Med. 2002;36:28-33
  19. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003:139:879-92
  20. Reed CE, Horpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, et al. Results of the American College of Surgeons Oncology Group Z0050: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126:1943-51 https://doi.org/10.1016/j.jtcvs.2003.07.030
  21. Gonzalez-Stawinski GV, Lemaire A, Merchant F, O'Halloran E, Coleman RE, Harpole DH, et al. A comparative analysis of positron emission tomography and mediastinoscopy in staging patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;126:1900-5 https://doi.org/10.1016/S0022-5223(03)01036-5
  22. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244-7 https://doi.org/10.1007/s002590050291
  23. 이승희, 조재화, 류정선, 이홍렬, 현인영, 곽승민. 폐암 병기 결정에서 CT와 PET-CT의 비교. 대한폐암학회지. 2004;4:44 (abstract)
  24. Boland GW, Goldberg MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MMet al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;194:131-4 https://doi.org/10.1148/radiology.194.1.7997539
  25. Erasmus JJ, Patz EF Jr, McAdams HP, Murray JG, Herndon J, Coleman RE, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168:1357-60 https://doi.org/10.2214/ajr.168.5.9129444
  26. Detterbeck FC, Jones DR, Molina PL. Extrathoracic staging. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and treatment of lung cancer: and evidence-bases guide for the practicing clinician. Philadelphia, PA: W.B. Saunders, 2004;94-1170
  27. Graeber GM, Gupta NC, Murray GF. Positron emission tomographic imaging with fluorodeozyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg 1999;117:917-27
  28. Gupta NC, Graeber GM, Rogers JS, Hishop HA. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg 1998;229:286-91 https://doi.org/10.1097/00000658-199902000-00018
  29. MacManus MP, Hicks RJ, Mattews JP, Hogg A, McKenzic AF, Wirth A, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-93 https://doi.org/10.1016/S0360-3016(01)01477-8
  30. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH. Et al. Preoperative staging of non-small cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-61 https://doi.org/10.1056/NEJM200007273430404
  31. Saunders CA, Dussek JE, O'Doherty MJ, Maisey M. Evaluation of fluorine-18-flurodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999;67:790-7 https://doi.org/10.1016/S0003-4975(98)01257-0
  32. Wan Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS mulicentre randomised trial. Lancet 2002;359:1388-92 https://doi.org/10.1016/S0140-6736(02)08352-6
  33. Weder W, Schmid RA, Bruchhaus H, Hillinger S, von Schulthess GK, Steinert H. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;66:886-92 https://doi.org/10.1016/S0003-4975(98)00675-4
  34. Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan. Ann Nucl Med 2002;16:263-71 https://doi.org/10.1007/BF03000105
  35. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996 37:1428-36